Chronic Hepatitis B Infection clinical trials

Explore recruiting chronic hepatitis b infection clinical trials.

Recruiting chronic hepatitis b infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Hepatitis B Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)

Denmark, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)

France, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Four-part, Randomized, Double-blind (Parts 1, 2A, 3 and 4), Multi-center, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK3965193 Monotherapy in Healthy Participants and in Participants Living with Chronic Hepatitis B Infection; and GSK3965193 in Combination with Bepirovirsen in Participants Living with Chronic Hepatitis B Infection

France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)

Germany, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.

Belgium, Germany, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Chronic Hepatitis B Infection trials by city

Chronic Hepatitis B Infection in Toronto Chronic Hepatitis B Infection in Vancouver Chronic Hepatitis B Infection in Montreal Chronic Hepatitis B Infection in Calgary Chronic Hepatitis B Infection in Edmonton Chronic Hepatitis B Infection in Ottawa Chronic Hepatitis B Infection in Winnipeg Chronic Hepatitis B Infection in Quebec City Chronic Hepatitis B Infection in Hamilton Chronic Hepatitis B Infection in Kitchener Chronic Hepatitis B Infection in London Chronic Hepatitis B Infection in Halifax Chronic Hepatitis B Infection in New York Chronic Hepatitis B Infection in Los Angeles Chronic Hepatitis B Infection in Chicago Chronic Hepatitis B Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease